ArticleChemical communications (Cambridge, England)2017
PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.
Article in Chemical communications (Cambridge, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Zwitterionic Modification of PSMA Ligands Reduces Off-Target Binding and Tissue Retention.Journal of medicinal chemistry · 2026Article
- Engineering NIR probes to enhance affinity and clinical workflow compatibility for prostate cancer imaging.bioRxiv : the preprint server for biology · 2025Article
- Prodrugs Targeting Prostate-Specific Membrane Antigen against Prostate Cancer.Journal of medicinal chemistry · 2025Review
- Prostate-specific membrane antigen-targeted surgery in prostate cancer: Accurate identification, real-time diagnosis, and precise resection.Theranostics · 2024Review
- Imageological/Structural Study regarding the Improved Pharmacokinetics byPharmaceuticals (Basel, Switzerland) · 2023Article
- Phototheranostics for multifunctional treatment of cancer with fluorescence imaging.Advanced drug delivery reviews · 2022Review
- Advances in PSMA-targeted therapy for prostate cancer.Prostate cancer and prostatic diseases · 2022Review
- Side-chain modification of collagen-targeting peptide prevents dye aggregation for improved molecular imaging of arthritic joints.Journal of photochemistry and photobiology. A, Chemistry · 2022Article
- Rapid Tumor Targeting of Renal-Clearable ZW800-1 Conjugate for Efficient Photothermal Cancer Therapy.Biomedicines · 2021Article
- Not so innocent: Impact of fluorophore chemistry on the in vivo properties of bioconjugates.Current opinion in chemical biology · 2021Review
- ZW800-PEG: A Renal Clearable Zwitterionic Near-Infrared Fluorophore for Potential Clinical Translation.Angewandte Chemie (International ed. in English) · 2021Article
- Article
- Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.Theranostics · 2021Article
- Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?Bioconjugate chemistry · 2020Review
- Tuned near infrared fluorescent hyaluronic acid conjugates for delivery to pancreatic cancer for intraoperative imaging.Theranostics · 2020Article
- A Fluorescent, [ACS chemical biology · 2019Article
- PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.Theranostics · 2019Review
- Emerging Fluorescent Molecular Tracers to Guide Intra-Operative Surgical Decision-Making.Frontiers in pharmacology · 2019Review
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Article
- Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.European journal of nuclear medicine and molecular imaging · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Prostate-specific membrane antigen (PSMA) can serve as a molecular cell surface target for the detection and treatment of prostate cancer. Near-infrared (NIR) fluorescence imaging enables highly sensitive, rapid, and non-radioactive imaging of PSMA, though specific targeting still remains a challenge because no optimized contrast agents exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.